Development and application of tumor diagnostic radioactive probe targeting folic acid receptor

Abstract

The present invention pertains to a novel liposome-based contrast agent that is for suppressing absorption in the reticuloendothelial system and for tumor-specific delivery of a radiolabeled substance. More specifically, the present invention pertains to: a liposome contrast agent containing a lipid and a compound of chemical formula 1, which is a radiolabeled substance, the liposome contrast agent being characterized in that the lipid is composed of (a) cholesterol, (b) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and (c) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy(polyethylene glycol)-2000] (DSPE-PEG2000); and a cancer diagnostic composition containing the liposome contrast agent as an active ingredient. If a liposome system, containing a contrast substance of chemical formula 1 having a unique lipid composition provided by the present invention, is manufactured, the tumor-to-organ uptake ratio of the contrast substance in the reticuloendothelial system increases significantly, thus greatly increasing the tumor diagnostic efficiency of the compound of chemical formula 1.

Claims

1. A liposome contrast agent consisting of a compound defined by Chemical Formula 1 and a lipid, wherein the lipid consists of (a) cholesterol; (b) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); and (c) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy (polyethyleneglycol)-2000] (DSPE-PEG2000): ##STR00012## wherein, X is a radioisotope of iodine, and k is in a range of 5≤k≤30, and wherein a molar ratio of (a):(b):(c) is 1:5 to 25:3 to 15.

2. The liposome contrast agent of claim 1, wherein X in the Chemical Formula 1 is a radioisotope of iodine selected from the group of consisting of .sup.123I, .sup.124I, .sup.125I, and .sup.131I.

3. The liposome contrast agent of claim 1, wherein the compound defined by the Chemical Formula 1 is hexadecyl-4-[.sup.131I]iodobenzoate defined by Chemical Formula 2: ##STR00013##

4. A liposome contrast agent consisting of a compound defined by Chemical Formula 1 and a lipid, wherein the lipid consists of: (a) cholesterol; (b) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); and (c-1) 1,2-distearoyl-cn-glycero-3-phosphoethanolamine-N[methoxy(polyethyleneglycol)-2000 (DSPE-PEG2000)]; and (c-2) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy(polyethyleneglycol)-2000-folate] (DSPE-PEG2000-folate): ##STR00014## wherein X is a radioisotope of iodine and k is in a range of 5≤k≤30, and wherein a molar ratio of (a):(b):(c-1):(c-2) is 1:5 to 25:2 to 8:1 to 7.

5. The liposome contrast agent of claim 1, wherein the contrast agent is used for optical imaging, positron emission tomography (PET) scanning, or single photon tomography (SPECT) scanning.

6. A method for diagnosing a cancer in a subject suspected for having a cancer, the method comprising: imaging the subject by administering an effective amount of a composition comprising the liposome contrast agent of claim 1 to the subject; and diagnosing the subject with the cancer based on imaging results.

7. The method of claim 6, wherein absorption of the compound defined by the Chemical Formula 1 is reduced in a reticuloendothelial system and absorption of the compound defined by the Chemical Formula 1 is increased in a folate receptor-overexpressing tumor.

8. The method of claim 7, wherein the folate receptor-overexpressing tumor is selected from the group consisting of pancreatic cancer, breast cancer, ovarian cancer, lung cancer, cervical cancer, colon cancer, melanoma, kidney cancer, brain tumor, myeloid leukemia, and head and neck cancer.

9. The method of claim 8, wherein the folate receptor-overexpressing tumor is pancreatic cancer.

Description

BRIEF DESCRIPTION OF DRAWINGS/FIGURES

(1) The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

(2) FIG. 1 shows the results of comparing degrees of HIB accumulation in tumors and other organs when liposomes were prepared with different composition ratios using DPPC, DPPG, cholesterol, and DSPE-PEG2000 (abbreviated as PEG).

(3) FIG. 2 shows the results examining the effect of DPPC or cholesterol on the delivery and the differential accumulation of HIB in tumors and other organs, respectively.

(4) FIG. 3 shows the effect on the delivery and the differential accumulation of HIB in tumors and other organs according to the folate attachment rate and shows the results confirming that the liposome composition of the present invention is specific for HIB only in contrast to HIB-ether.

(5) FIG. 4A and FIG. 4B show the results of SPECT imaging using the liposome contrast agent of the present invention in pancreatic cancer-induced mice (FIG. 4A) and normal mice (FIG. 4B).

(6) FIG. 5 shows the results evaluating degrees of absorption of liposomes according to the present invention in tumor cells or normal cells derived from various tissues.

(7) FIG. 6 shows the PET imaging results 24 hours after administration of the liposome contrast agent according to the present invention to the tail vein after establishing a mouse xenograft model by injecting two different types of pancreatic cancer cells (PANC-1, MIA PaCa-2) with varying levels of folate receptor expression into both flanks of a single mouse, respectively.

(8) FIG. 7 shows the results evaluating the accumulation amount (% ID/g) of the liposome contrast agent in each tissue 24 hours after administration of the liposome contrast agent according to the present invention to the tail vein of the cervical cancer cell xenograft model.

(9) FIG. 8 shows the results evaluating the accumulation amount (% ID/g) of the liposome contrast agent in each tissue 24 hours after administration of the liposome contrast agent according to the present invention to the tail vein of the ovarian cancer cell xenograft model.

(10) FIG. 9 shows the results evaluating the accumulation amount (% ID/g) of the liposome contrast agent in each tissue 24 hours after administration of the liposome contrast agent according to the present invention to the tail vein of the skin cancer (melanoma) cell xenograft model.

(11) FIG. 10 shows the results evaluating the accumulation amount (% ID/g) of the liposome contrast agent in each tissues 24 hours after administration of the liposome contrast agent according to the present invention to the tail vein of the colon cancer cell xenograft model.

(12) FIG. 11 shows PET imaging results 24 hours after administration of the liposome contrast agent according to the present invention to the tail vein of the xenograft models using CT26 colorectal cancer cells or 4T1 and MDA-MB-231 breast cancer cells.

(13) FIG. 12A and FIG. 12B show the establishment process of the pancreatic cancer orthotopic animal model (FIG. 12A), and the images (FIG. 12B) captured using PET and the optical imaging device (IVIS) 24 hours after administration of the liposome contrast agent according to the present invention to the tail vein of the established pancreatic cancer orthotopic animal model.

(14) FIG. 13A, FIG. 13B or FIG. 13C each confirms the establishment of a breast cancer bone metastasis mouse model (FIG. 13A), and shows the PET imaging results 24 hours after administration of the contrast agent of the present invention after verifying the location of the metastasized tumor in the leg bone using luciferin luminescence imaging and the PET imaging results 1 hour after administration of [.sup.18F] FDG to the tail vein in the same mouse model (FIG. 13B), or shows the PET or IVIS imaging results 24 hours after administration of the liposome contrast agent according to the present invention to the tail veins of the breast cancer lung metastasis model (FIG. 13C).

MODE FOR CARRYING OUT INVENTION

(15) Hereinafter, the present invention will be described in more detail with reference to examples, experimental examples and manufacturing examples. However, the following examples, experimental examples and preparation examples are illustrative of the present invention, and the present invention is not limited to the following examples, experimental examples and manufacturing examples.

Example 1: Preparation of Liposomes Specialized for HIB

(16) DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DPPG (1,2-dihexadecanoyl-sn-glycero-3-phospho-3-(1′-rac-glycero)), cholesterol, DSPE-PEG2000 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[methoxy (polyethyleneglycol)-2000]; abbreviated as PEG in figures and tables) were mixed according to the molar ratios as shown in FIG. 1 and FIG. 2, respectively (see Table 1 below). After mixing [.sup.131I] HIB, thus prepared mixture was dried to obtain a thin lipid film. The lipid membrane was hydrated in saline for 25 minutes. Opaque liposome solution obtained as a result of hydration was extruded using a 100 nm membrane filter and further purified using a size exclusion column (PD-10, GE Healthcare), which generated liposome contrast agents loaded with [.sup.131I] HIB having various lipid compositions.

(17) TABLE-US-00001 TABLE 1 No. Lipid composition 1 DPPC:DPPG:cholesterol:PEG = 8:1:3:1 2 DPPC:DPPG:cholesterol:PEG = 1:8:3:1 3 DPPC:DPPG:cholesterol:PEG = 8:1:3:7 4 DPPC:DPPG:cholesterol:PEG = 1:8:3:7 5 DPPC:DPPG:cholesterol:PEG = 8:8:7:7 6 DPPC:DPPG:cholesterol:PEG = 8:8:0:7 7 DPPG:cholesterol:PEG = 12:1:7 8 DPPC:cholesterol:PEG = 12:1:7

(18) Afterwards, in order to examine in vivo distribution of liposomes of each composition in the mouse tumor model, experiments to verify biodistribution were performed by injection the liposome contrast agents (20 μCi) into the tail veins of CT26 cancer-BALB/C mice.

(19) As a results as shown in FIG. 1, it was observed that the uptake of [.sup.131I] HIB-labeled liposomes in the blood was maintained high while tumor uptake was at the level of 1% ID/g in the case of the liposome composition with reduced DPPG ratio. In addition, the liposome composition with reduced DPPC ratio showed a generally low uptake in the organ after injection and rapidly discharged into the body, while tumor uptake was significantly low.

(20) And, as shown in FIG. 2, in the case of the compositions containing no cholesterol, the overall uptake of [.sup.131I] HIB-labeled liposomes in the organs is reduced a lot, and the uptake in the tumors was not high either. On the contrary, in the case of the composition containing high cholesterol, the overall uptake in the organs increased and the intake in the tumors slightly increased. In addition, from the results from liposomes containing certain levels of cholesterol and PEG and only single type of lipid, (DPPG/DPPC:cholesterol:DSPE-PEG2000=12:1:7), it was observed that the difference in the uptake of tumors varied abruptly depending on the types of lipid. These findings suggest that the resulting effect cannot be predicted based on the specific types of lipid and composition ratios constituting liposomes even in the presence of PEG despite the previous report that inclusion of PEG generally reduced the liposome uptake in reticuloendothelial organs such as liver and spleen.

(21) In the composition of liposomes using only DPPG as lipid, spleen uptake was particularly increased, and tumor uptake was markedly low. These results confirmed that the composition of liposomes greatly influenced the uptake by tumors and reticuloendothelial system, and the release and discharge of HIB loaded on the liposomes. It was also noted that a specific liposome composition ratio is required resulting the optimal outcome in the tumor diagnosis using HIB.

Example 2: Verification of the HIB Specialization and the Effect of Folate Attachment Ratio

(22) 1-(hexadecyloxy)-4-iodobenzene (HIB-ether) was synthesized and radiolabeled with .sup.131I to prepare [.sup.131I] HIB-ether defined by the following Chemical Formula 7. After synthesizing liposomes with the lipid composition (see Table 2) shown in FIG. 3 using the same method as in Example 1, the liposome contrast agent according to Table 2 (20 μCi) was injected into the tail vein of the mouse grafted with pancreatic cancer cells (PANC-1) and biodistribution comparison experiments were performed 24 hours later.

(23) ##STR00011##

(24) TABLE-US-00002 TABLE 2 Type Lipid composition Folate-[.sup.131I]HIB- DPPC:Cholesterol:DSPE-PEG2000:DSPE- liposome PEG2000-folate = 12:1:5:2 Folate-[.sup.131I]HIB-ether- DPPC:Cholesterol:DSPE-PEG2000:DSPE- liposome PEG2000-folate = 12:1:5:2 Folate-[.sup.131I]HIB- DPPC:Cholesterol:DSPE-PEG2000-folate = liposome(No PEG) 12:1:2

(25) In Table 2, “Folate-[.sup.131I]HIB-liposome” means that [.sup.131I]HIB is loaded in the liposomes having the lipid composition shown in the above table. The “Folate-[.sup.131I]HIB-ether-liposome” indicates that [.sup.131I]HIB-ether is loaded on the liposomes having the lipid composition shown in the above table. The “Folate-[.sup.131I]HIB-liposome (No PEG)” refers to the liposomes loaded with [.sup.131I]HIB having the lipid composition shown in the above table.

(26) As shown in FIG. 3, the uptake of folate-[.sup.131I]HIB-ether-liposome was higher than that of folate-[.sup.131I]HIB-liposome in most organs, and the degrees of [.sup.131I] HIB uptake for pancreatic cancer were similar. In particular, it was observed that the difference between the uptake of liver and spleen was very large, and liver and spleen uptake of folate-[.sup.131I]HIB-ether-liposome was much higher than folate-[.sup.131I]HIB-liposome, which also increased the background noise level. In addition, liposomes of the composition excluding DSPE-PEG2000 (folate-[.sup.131I]HIB-liposome (no PEG)) showed similar uptake pattern to folate-[.sup.131I]HIB-liposome in most organs, while the degree of uptake in the liver was 6 times higher, and in contrast, it reduced down to approximately half level in the pancreatic cancer. On the basis of these results, use of HIB as a radioactive tracer is better for obtaining clear tumor images than that of HIB-ether for the diagnosis of pancreatic cancer, considering the uptake ratio of each organs and tumors (ratios of tumor to liver or spleen). In addition, the composition ratio constituting the liposomes was also found to be a very important factor in the effective diagnosis of the tumor.

(27) FIG. 4 shows the SPECT imaging results from the application of the liposome contrast agent of the present invention in pancreatic cancer-induced mice (A) and normal mice (B). In the pancreatic cancer model, it can be seen that the tumor is very clearly imaged compared to other neighboring organs.

Example 3: Evaluation of Cellular Uptake of the Liposome Contrast Agent In Vitro

(28) To evaluate the degrees of absorption of folate-[.sup.124I]HIB-liposome prepared in Example 2 in tumor cells, tumor cells and normal cells derived from various tissues were examined for in vitro cellular uptake capacity.

(29) After dispensing tumor cells or normal cells derived from each tissue 1×10.sup.5 cells per well and allowing to adhere onto the surface of the culture dish, the folate receptor-targeting liposome contrast agents prepared in Example 2 (folate-[.sup.124I] HIB-liposome) were applied, and the experiment was conducted to compare the degrees of cellular intake 12 hours and 24 hours after the treatment. Normal cells: BNL CL.2 (liver), HEK293 (kidney), Raw264.7 (macrophage) Tumor cells: MDA-MB-231 (breast cancer), B16F10 (melanoma), HeLa (cervical cancer), SKOV3 (ovarian cancer), CT26 (colorectal cancer), 4T1 (breast cancer)

(30) Specifically, the cells were divided into 6 well plates 24 hours before the experiment and allowed to sufficiently adhere to the surface of the culture plate, then treated with folate receptor-targeting liposome contrast agent (folate-[.sup.124I]HIB-liposome), 2 μCi per well. Subsequently cells were placed in the incubator for 12 hours or 24 hours and cultured for the time to ingest the liposomes.

(31) After 12 hours and 24 hours, cells corresponding to each condition were first washed three times with PBS to remove all liposomes which did not get ingested into the cells, and then treated with trypsin-EDTA solution to release the cells from the bottom of the plate, transferred to a tube prepared in advance, and tubes corresponding to each condition was measured for radioactivity using gamma counter to check the cellular uptake.

(32) The results are shown in FIG. 5.

(33) Folate receptors are known to be expressed at higher levels in tumor cells than normal cells. As can be seen in FIG. 5, it was confirmed that the liposome contrast agent according to the present invention is uptaken greater in tumor cells overexpressing folate receptors compared with normal cells, proving that it can be useful as a radioactive probe for diagnosing various tumors.

Example 4: Confirmation of Specificity for Folate Receptor In Vivo

(34) Two types of pancreatic cancer cells (PANC-1, MIA PaCa-2) were used for the pancreatic cancer xenograft models for the experiments. PANC-1 was characterized by overexpressing folate receptors, while MIA PaCa-2 is a pancreatic cancer cell line reported to have lower expression of folate receptors.

(35) After injecting two types of pancreatic cancer cells into each flank of the same mouse to establish a xenograft model, the liposome contrast agent folate-[.sup.124I]HIB-liposome) was injected into the tail vein (200 μCi) and PET scanning was carried out 24 hours later.

(36) The results for this are shown in FIG. 6.

(37) As shown in FIG. 6, signals were detected in both types of pancreatic cancer cells, but it was confirmed that a stronger signal was detected in the area grafted with PANC-1 cells overexpressing folate receptors. Namely, it can be said that the liposome contrast agent according to the present invention can diagnose tumors by actively targeting folate receptors.

Example 5: Evaluation of Liposome Absorption In Vivo

(38) After confirming that the liposome contrast agent according to the present invention exhibits a very high absorption rate specifically for tumor cells in Example 3, the degrees of absorption of the liposome contrast agent in various tissues transplanted with tumor cells in the mouse model were measured.

Example 5-1: Xenograft Mouse Model

(39) Cervical cancer cells (HeLa cells), ovarian cancer cells (SKOV3 cells), skin cancer (melanoma) cells (B16F10 cells) or colon cancer cells (CT26 cells) were injected in the right flank of mice. When tumors grew to a size of less than 1 cm, each organ was extracted 24 hours after the injection and the degree of absorption of the liposomes was evaluated.

(40) The results are shown in FIG. 7 to FIG. 10.

(41) As can be seen in FIG. 7, the results of the cervical cancer xenograft model using HeLa cells confirmed that the uptake of the tumor, which was 5.5% ID/g, was the highest among other tissues. The ratio of uptake comparing tumor tissues versus other tissues showed even greater differences, indicating it can be utilized to diagnose cervical cancer tissues specifically (tumor-to-muscle ratio=68.6-fold, tumor-to-blood ratio=53.7-fold, tumor-to-liver ratio=10.8, tumor-to-spleen=3.6 fold).

(42) As can be seen in FIG. 8, the result for the ovarian cancer xenograft model using SKOV3 cells confirmed that the uptake of the tumor was 4.5% ID/g, highest among the tissues. The ratio of uptake comparing tumor tissues versus other tissues showed even greater differences, indicating it can be utilized to diagnose ovarian cancer tissues specifically (tumor-to-muscle ratio=55.1-fold, tumor-to-blood ratio=61.7-fold, tumor-to-liver ratio=10.5, tumor-to-spleen=4.7 fold).

(43) As can be seen in FIG. 9, the result for the ovarian cancer xenograft model using SKOV3 cells showed that the uptake of the tumor was 4.5% ID/g, which was highest among other tissues. Furthermore, the ratio of uptake comparing tumor tissues versus other tissues also showed even larger differences, confirming that it could be used to specifically diagnose ovarian cancer only (tumor-to-muscle ratio=54.0 times, tumor-to-blood ratio=45.1 times, tumor-to-liver ratio=7.3 times, tumor to spleen ratio=2.2).

(44) As can be seen in FIG. 10, colorectal cancer xenograft model using CT26 cells generated similar results in that the tumor uptake was 5.2% ID/g, highest among other tissues. In addition, the ratio of uptake comparing tumor tissues versus other tissues also showed even larger differences, confirming that it could be used to specifically diagnose colorectal cancer only (tumor-to-muscle ratio=73.5 times, tumor-to-blood ratio=64.5 times, tumor-to-liver ratio=8.9 times, tumor to spleen ratio=4.8).

(45) On the other hand, the present inventors conducted nuclear imaging experiments using PET besides biodistribution experiments to evaluate whether the liposome contrast agent according to the present invention can be used as a radioactive probe for tumor diagnosis.

(46) Briefly, the liposome contrast agent (folate-[.sup.124I]HIB-liposome) was injected into the tail vein (200 μCi) of xenograft models of breast cancer cells 4T1, MDA-MB-231 or colorectal cancer cells CT26. PET images were obtained 24 hours after the injection, and results observed.

(47) The results are shown in FIG. 11.

(48) As shown in FIG. 11, it was confirmed that absorption in tissues where reticulum endothelial system (RES) is distributed, such as liver and spleen, was very low and tumor-specific absorption was highest in the PET images. Based on this results, it was again proven that the liposome contrast agent according to the present invention can be very useful for diagnosing tumors overexpressing folate receptors.

(49) 5-2: Orthotopic Mouse Model

(50) To evaluate the active target-oriented activity of the liposome contrast agent in the orthotopic model rather than the xenograft model, an orthotopic model of pancreatic cancer was established, and following experiments were conducted (FIG. 12A).

(51) First, we used PANC-1/Luc+ cells expressing luminescence enzymes called luciferase to check the incidence of tumors in the abdominal cavity. These cells were injected at the tip of the pancreas, and 21 days later, it was confirmed that the orthotopic model was well established by luminescence images using IVIS and ensuing experiments were carried out.

(52) PET images were obtained 24 hours after the injection of the liposome contrast agent (folate-[.sup.124I]HIB-liposome) into the tail vein (200 μCi) of the established pancreatic cancer orthotopic model. Then, when the abdomen was opened, IVIS was used to obtain Cerenkov luminescent images of the liposome contrast agent and a luminescence images using luciferin to identify tumor cells.

(53) The results are shown in FIG. 12B.

(54) As can be seen in FIG. 12B, it was confirmed that the liposome contrast agent was ingested at a very high concentration in the pancreatic cancer in the PET images. In the luminescence images taken by IVIS when the abdomen was opened, Cerenkov luminescence and luciferin luminescence were detected in the same pancreatic region, directly confirming that the region showing high levels of signal in the PET images was the pancreatic cancer.

Example 6: Evaluation of Tumor Diagnosis Capability in the Breast Cancer Metastasis Model

(55) In the case of breast cancer, it is understood that it easily metastasizes to surrounding tissues and other body parts outside the breast, and in particular, metastasis to bone is known to occur frequently.

(56) The present inventors conducted experiments to check whether metastasis of breast cancer can be diagnosed early through PET imaging after 24 hours of injecting the liposome contrast agent according to the present invention.

(57) For the breast cancer metastasis model, MDA-MB-231/Luc+ was used, and after 10 days of direct injection of 1×10.sup.5 cells into the left ventricle, IVIS-assisted luminescence images confirmed that bone metastasis occurred to the femoral bones. After verifying the establishment of bone metastasis model of breast cancer, further experiments were carried out (FIG. 12A). PET imaging experiments were performed 24 hours after injection of the liposome contrast agent (folate-[.sup.124I]HIB-liposome) into the tail vein (200 μCi) of the breast cancer bone metastasis mouse, and PET imaging experiments for comparison using [.sup.18F]FDG (imaging experiment 1 hour after injection into the tail vein), which is commonly used for tumor diagnosis, were performed in parallel.

(58) The results are shown in FIG. 13B.

(59) As shown in FIG. 13B, in the case of the mice to which the liposome contrast agent according to the present invention was administered, the PET signal was detected in the region exactly matched with the bone metastasis region of the breast cancer cells identified by the luciferin emission image. However, PET images obtained by injecting FDG, which is used as a tumor diagnostic PET probe in the clinic, into the same mouse were difficult to identify the tumor site clearly due to high background uptake.

(60) Meanwhile, a lung metastasis model was prepared by injecting another breast cancer cell 4T1/Luc+ cells (1×10.sup.5) into tail vein and establishment of the metastasis model was confirmed by detecting high signals in the lung using luciferin luminescence imaging. After the injection of the liposome contrast agent (folate-[.sup.124I]HIB-liposome) according to the present invention into the tail vein of the lung metastasis model (200 μCi), the PET was scanned, which showed that lung metastasis can be diagnosed clearly as well. By confirming that the signal is well matched with the signal for metastatic breast cancer cells in the luminescence image, it was determined that the strong signal of the PET images was due to tumor cells metastasized to the lung (FIG. 13C).

INDUSTRIAL APPLICABILITY

(61) As described so far, the present invention relates to a novel liposome-based contrast agent for the inhibition of reticuloendothelial absorption and tumor-specific delivery of radioactive tracers, and more particularly to a liposome contrast agent characterized by consisting of a compound defined by Chemical Formula 1 as a radioactive tracer and lipid, wherein the lipid is characterized by consisting of (a) cholesterol; (b) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); and (c) 1,2-dstearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy (polyethyleneglycol)-2000 (DSPE-PEG2000) and a cancer diagnostic composition containing the same as an active ingredient.

(62) When a liposome system equipped with a contrast agent of Chemical Formula 1 with a unique lipid composition provided by the present invention is prepared, the tumor-to-organ uptake ratio in tumors compared to RES organs is significantly increased, highly enhancing diagnostic efficiency of the compound of Chemical Formula 1 for tumors, therefore it is highly industrially applicable as a diagnostic tool.